Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Evanthia Galanis MD

Evanthia Galanis MD

Professor of Oncology, Sandra J. Schulze Professor of Novel Therapeutics, Mayo Clinic, Rochester, Minnesota

Dr. Evanthia Galanis is a Professor of Oncology and the Sandra J. Schulze Professor of Novel Therapeutics at the Mayo Clinic. She is the Chair of the Brain Tumor Committee of the cooperative group Alliance for Clinical Trials in Oncology and Group Chair-elect,  a board member for the National Brain Tumor Society (NBTS), co-Chair of NCI’s GBM/Brain Metastases interest Group and member of the Brain Malignancies Steering Committee.

Disclosures

Relevant disclosures include participation in a Servier Advisory Board with honoraria to my institution.

Recent Contributions to PracticeUpdate:

  1. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma